{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:29:22Z","timestamp":1791584962838,"version":"4.3.4"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"AIRC Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jconrel.2026.115194","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:40:57Z","timestamp":1784734857000},"page":"115194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["aCD47\u2013docetaxel immuno-chemotherapy: A two-pronged attack against \u2018cold\u2019 glioblastoma"],"prefix":"10.1016","volume":"398","author":[{"given":"Anna Lisa","family":"Palange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Span\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Susana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"L\u00f3pez-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Giuseppe","family":"Furnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Albanesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Lugli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Di Mascolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Decuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jconrel.2026.115194_bb0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrclinonc.2017.171","article-title":"Surgical oncology for gliomas: the state of the art","volume":"15","author":"Sanai","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0015","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1038\/s41598-020-68011-4","article-title":"Longer-term (\u2265 2 years) survival in patients with glioblastoma in population-based studies pre-and post-2005: a systematic review and meta-analysis","volume":"10","author":"Poon","year":"2020","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115194_bb0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115194_bb0025","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115194_bb0030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115194_bb0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115194_bb0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-010-0501-5","article-title":"Measurement of psychological distress in patients with intracranial tumours: the NCCN distress thermometer","volume":"104","author":"Goebel","year":"2011","journal-title":"J. Neuro-Oncol."},{"issue":"67","key":"10.1016\/j.jconrel.2026.115194_bb0045","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.22802","article-title":"Correlation of psychooncological distress-screening and quality of life assessment in neurosurgical patients","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11060-022-04123-3","article-title":"Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation","volume":"160","author":"Shidoh","year":"2022","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-022-01260-z","article-title":"Signaling pathways in brain tumors and therapeutic interventions","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115194_bb0060","first-page":"1","article-title":"Cancer therapy with antibodies","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115194_bb0065","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115194_bb0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.jconrel.2026.115194_bb0075","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115194_bb0080","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"issue":"7785","key":"10.1016\/j.jconrel.2026.115194_bb0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","article-title":"Longitudinal molecular trajectories of diffuse glioma in adults","volume":"576","author":"Barthel","year":"2019","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.jconrel.2026.115194_bb0090","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","article-title":"Glioblastoma heterogeneity at single cell resolution","volume":"42","author":"Eisenbarth","year":"2023","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115194_bb0095","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro-oncology"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro-oncology"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115194_bb0105","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115194_bb0110","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41571-021-00518-9","article-title":"The immune landscape of common CNS malignancies: implications for immunotherapy","volume":"18","author":"Ott","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115194_bb0115","first-page":"1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"issue":"7738","key":"10.1016\/j.jconrel.2026.115194_bb0125","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"7985","key":"10.1016\/j.jconrel.2026.115194_bb0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115194_bb0135","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/neuonc\/noad092","article-title":"Cell-based therapies for glioblastoma: promising tools against tumor heterogeneity","volume":"25","author":"Nehama","year":"2023","journal-title":"Neuro-oncology"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0140","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1038\/s41467-025-63692-9","article-title":"Post-resection delivery of a TLR7\/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice","volume":"16","author":"Graham-Gurysh","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115194_bb0150","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115194_bb0155","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2306973121","article-title":"Multimodal neuro-nanotechnology: challenging the existing paradigm in glioblastoma therapy","volume":"121","author":"Kudruk","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.115194_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113951","article-title":"Rationally designed drug delivery systems for the local treatment of resected glioblastoma","volume":"177","author":"Bastiancich","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115194_bb0165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jconrel.2024.01.072","article-title":"Locoregional drug delivery for cancer therapy: preclinical progress and clinical translation","volume":"367","author":"Shaha","year":"2024","journal-title":"J. Control. Release"},{"issue":"8956","key":"10.1016\/j.jconrel.2026.115194_bb0170","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","article-title":"Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas","volume":"345","author":"Brem","year":"1995","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115194_bb0175","first-page":"707","article-title":"Interstitial chemotherapy with biodegradable BCNU (Gliadel\u00ae) wafers in the treatment of malignant gliomas","volume":"3","author":"Bota","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115194_bb0180","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/bjc.2015.421","article-title":"Has the survival of patients with glioblastoma changed over the years?","volume":"114","author":"Desouza","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archinte.1990.00390130145023","article-title":"Complications associated with Ommaya reservoirs in patients with cancer: the Princess Margaret hospital experience and a review of the literature","volume":"150","author":"Lishner","year":"1990","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0190","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1038\/s41598-023-31811-5","article-title":"Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models","volume":"13","author":"Gherardini","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115194_bb0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.actbio.2020.11.030","article-title":"Biocompatible copolymer formulations to treat glioblastoma multiforme","volume":"121","author":"Erthal","year":"2021","journal-title":"Acta Biomater."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115194_bb0200","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.apsb.2023.06.010","article-title":"An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma","volume":"13","author":"Qiu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.115194_bb0205","article-title":"In situ administration of STING-activating hyaluronic acid conjugate primes anti-glioblastoma immune response","volume":"26","author":"Chellen","year":"2024","journal-title":"Mater. Today Bio"},{"issue":"46","key":"10.1016\/j.jconrel.2026.115194_bb0210","doi-asserted-by":"crossref","first-page":"23838","DOI":"10.1039\/D0NR05053A","article-title":"Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma","volume":"12","author":"Brachi","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.115194_bb0215","first-page":"1","article-title":"Local delivery of doxorubicin prodrug via lipid nanocapsule\u2013based hydrogel for the treatment of glioblastoma","author":"Wang","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115194_bb0220","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1021\/acs.biomac.3c00846","article-title":"Microneedle patch delivery of PLCG1-siRNA efficient enhanced temozolomide therapy for glioblastoma","volume":"25","author":"Yang","year":"2024","journal-title":"Biomacromolecules"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115194_bb0225","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/2015.1.FOCUS14743","article-title":"Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals","volume":"38","author":"Wang","year":"2015","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.jconrel.2026.115194_bb0230","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2147\/OTT.S159913","article-title":"Delivery of bevacizumab by intracranial injection: assessment in glioma model","author":"Liu","year":"2018","journal-title":"Onco. Targets Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115194_bb0235","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","article-title":"Repeated blood\u2013brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial","volume":"24","author":"Sonabend","year":"2023","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0240","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3171\/2016.1.JNS151591","article-title":"Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies","volume":"126","author":"Jahangiri","year":"2017","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0250","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0255","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1038\/s41467-020-17704-5","article-title":"Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types","volume":"11","author":"Khalsa","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115194_bb0260","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41565-021-00879-3","article-title":"Conformable hierarchically engineered polymeric micromeshes enabling combinatorial therapies in brain tumours","volume":"16","author":"Di Mascolo","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115194_bb0265","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3171\/2021.11.FOCUS21556","article-title":"Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes","volume":"52","author":"Letchuman","year":"2022","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.jconrel.2026.115194_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.692142","article-title":"Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis","volume":"11","author":"Kartikasari","year":"2021","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.jconrel.2026.115194_bb0275","doi-asserted-by":"crossref","first-page":"7941","DOI":"10.1158\/0008-5472.CAN-07-1622","article-title":"Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from \u201csilent\u201d to immunogenic","volume":"67","author":"Obeid","year":"2007","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115194_bb0280","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/neuonc\/noaa050","article-title":"Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine","volume":"22","author":"Liu","year":"2020","journal-title":"Neuro-oncology"},{"issue":"47","key":"10.1016\/j.jconrel.2026.115194_bb0285","doi-asserted-by":"crossref","first-page":"23714","DOI":"10.1073\/pnas.1906346116","article-title":"Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115194_bb0290","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1084\/jem.20180684","article-title":"High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors","volume":"215","author":"Brummelman","year":"2018","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0295","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1038\/s41467-023-40790-0","article-title":"CRUSTY: a versatile web platform for the rapid analysis and visualization of high-dimensional flow cytometry data","volume":"14","author":"Puccio","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115194_bb0300","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41590-022-01219-w","article-title":"Stem-like\u2019precursors are the fount to sustain persistent CD8+ T cell responses","volume":"23","author":"Zehn","year":"2022","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115194_bb0305","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115194_bb0310","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115194_bb0315","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.apsb.2022.12.016","article-title":"Building on the backbone of CD47-based therapy in cancer: combination strategies, mechanisms, and future perspectives","volume":"13","author":"Ye","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0320","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1038\/s41467-023-40579-1","article-title":"Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment","volume":"14","author":"Cai","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115194_bb0325","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.1721434116","article-title":"Microglia are effector cells of CD47-SIRP\u03b1 antiphagocytic axis disruption against glioblastoma","volume":"116","author":"Hutter","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0330","doi-asserted-by":"crossref","first-page":"8990","DOI":"10.1038\/s41467-025-64020-x","article-title":"Size-variable self-feedback nanomotors for glioblastoma therapy via mitochondrial mineralization","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0335","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41467-024-44963-3","article-title":"Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0340","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41467-020-15129-8","article-title":"Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity","volume":"11","author":"von Roemeling","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0345","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41467-022-29137-3","article-title":"Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.jconrel.2026.115194_bb0350","doi-asserted-by":"crossref","first-page":"14145","DOI":"10.1021\/acsnano.3c03409","article-title":"Matrix metalloproteinase-and pH-sensitive nanoparticle system enhances drug retention and penetration in glioblastoma","volume":"18","author":"Dosta","year":"2024","journal-title":"ACS Nano"},{"issue":"18","key":"10.1016\/j.jconrel.2026.115194_bb0355","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2204621120","article-title":"Self-assembling paclitaxel-mediated stimulation of tumor-associated macrophages for postoperative treatment of glioblastoma","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115194_bb0360","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41467-022-29383-5","article-title":"cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies","volume":"13","author":"Pedersen","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115194_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224137","article-title":"Statistical determination of synergy based on Bliss definition of drugs independence","volume":"14","author":"Demidenko","year":"2019","journal-title":"PLoS One"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:56:41Z","timestamp":1790211401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926005973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":73,"alternative-id":["S0168365926005973"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115194","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"aCD47\u2013docetaxel immuno-chemotherapy: A two-pronged attack against \u2018cold\u2019 glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115194"}}